Quinn Nazarewycz's Colleagues at QED Therapeutics
Sam Casillas
Head of KOL Advocacy Development, Oncology/Rare Disease Marketing & Commercialization
Quinn Nazarewycz's Contact Details
HQ
650-231-4088
650-231-4088
Location
Company
QED Therapeutics
QED Therapeutics
Quinn Nazarewycz's Company Details
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Frequently Asked Questions about Quinn Nazarewycz
Quinn Nazarewycz currently works for QED Therapeutics.
Quinn Nazarewycz's role at QED Therapeutics is Senior Director, Marketing.
Quinn Nazarewycz's email address is ***@qedtx.com. To view Quinn Nazarewycz's full email address, please signup to ConnectPlex.
Quinn Nazarewycz works in the Biotechnology industry.
Quinn Nazarewycz's colleagues at QED Therapeutics are Jennifer Lai, Shivani Pandit, Chelsea Guiseppi, Sam Casillas, Deborah Mortensen, Yvonne Stone, Roshni Khanna and others.
Quinn Nazarewycz's phone number is 650-231-4088